Key Points
- Glaukos CFO Alex Thurman sold 20,000 shares for approximately $3.6 million at an average price of $180.13, reducing his ownership by 31.3%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Glaukos shares traded near their 12-month high, opening at $182.97, while the company reported quarterly revenue of $185.61 million—up 49.6% year over year—and a smaller-than-expected loss.
- Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $177.33; institutional investors own approximately 99.04% of the company.
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 20,000 shares of Glaukos stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the transaction, the chief financial officer owned 43,906 shares in the company, valued at $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Glaukos Trading Up 0.9%
NYSE:GKOS opened at $182.97 on Wednesday. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $184.00. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The stock's 50 day simple moving average is $147.23 and its 200-day simple moving average is $128.06. The firm has a market cap of $10.79 billion, a P/E ratio of -56.30 and a beta of 0.78.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same period last year, the company earned ($0.24) earnings per share. The company's revenue for the quarter was up 49.6% on a year-over-year basis. Equities analysts anticipate that Glaukos Corporation will post -0.35 EPS for the current year.
Wall Street Analysts Forecast Growth
GKOS has been the subject of several analyst reports. Wall Street Zen raised shares of Glaukos from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Truist Financial raised their price target on Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a report on Thursday, July 30th. UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 price target on the stock. Citigroup increased their price objective on Glaukos from $175.00 to $188.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, William Blair reissued an "outperform" rating on shares of Glaukos in a report on Tuesday, May 26th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $177.33.
Get Our Latest Report on Glaukos
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Glaukos during the 2nd quarter worth approximately $1,333,318,000. Janus Henderson Group PLC increased its stake in Glaukos by 77.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock valued at $575,844,000 after purchasing an additional 2,329,608 shares in the last quarter. Wellington Management Group LLP increased its stake in Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier's stock valued at $292,004,000 after purchasing an additional 336,266 shares in the last quarter. Primecap Management Co. CA raised its holdings in Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier's stock worth $381,289,000 after purchasing an additional 1,123,140 shares during the last quarter. Finally, State Street Corp raised its holdings in Glaukos by 0.9% during the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier's stock worth $239,640,000 after purchasing an additional 18,040 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
